Table 2.
Summarized of clinical data investigating anti-EGFR therapy on HPV-positive HNSCC.
| References (Study) | Treatment | HPV positivity analysis | Result |
|---|---|---|---|
| Recurrent and metastatic HNSCC | |||
| Vermorken et al. (45) (SPECTRUM) |
Cisplatin and fluorouracil ± panitumumab | Prospective | Addition of panitumumab to cisplatin-based chemotherapy significantly improves OS and PFS only in HPV negative HNSCC patients |
| Vermorken et al. (90) (EXTREME) |
Cisplatin and fluorouracil ± cetuximab | Retrospective | Survival benefit of adding cetuximab to platinum-based chemotherapy was independent of p16 status |
| Fayette et al. (111) (MEHGAN) |
Cetuximab vs. cetuximab- duligotuzumab. | Prospective | HPV-negative HNSCC but not HPV-positive are most likely to respond to EGFR blockage by cetuximab or duligotuzumab. |
| Seiwert et al. (112) (BIBW 2992 trial) |
Afatinib vs. cetuximab | Prospective | HPV positive HNSCC patients had a lower response rate to EGFR inhibitors compared with HPV negative patients |
| Locally advanced HNSCC | |||
| Pajares et al. (113) (Restrospective series) |
Cisplatin-RT vs. cetuximab-RT | Retrospective series | p16-positive patients may benefit more from RT combined with EGFR inhibitors than with cisplatin |
| Koutcher et al. (114) (Retrospective series) |
Cisplatin-RT vs. cetuximab-RT | Retrospective series | Treatment with cisplatin not cetuximab predict for better OS, FFS and locoregional control |
| Ang et al. (36) (RTOG 0522 study) |
Cisplatin ± cetuximab with AFX RT | Prospective | The addition of cetuximab produce no benefit in PFS or OS in patient with p16 positive or negative HNSCC |
| Rosenthal et al. (101) (IMCL-9815 phase III Study) |
RT vs. cetuximab-RT | Retrospective | Better outcomes in both groups p16-positive and p16-negative when treated with cetuximab and RT in comparison with RT alone |
| Mesía et al. (115) (CONCERT-1) |
Cisplatin-RDT ± panitumumab | Prospective | No benefit was noted with the addition of panitumumab in either PFS or OS in the patients with p16-postive tumors |
| Giralt et al. (16) (CONCERT-2) |
Panitumumab-RT vs. cisplatin-RT | Prospective | Better outcomes for cisplatin-RT (few p16 positive patients included) |
| Ou et al. (116) (Retrospective series) |
Cisplatin-RT vs. cetuximab-RT | Restrospective series | Better outcomes in patients receiving concurrent cisplatin over cetuximab regardless of HPV/p16 status |
| Mena et al. (117) (Retrospective series) |
Cisplatin-RT vs. cetuximab-RT vs. surgery/RT vs. ICT/RT | Retrospective series | Improved OS for all treatment schemes with the exception of those who underwent cetuximab-RT |
AFX RT, Accelerated fractionation radiotherapy; HNSCC, Head and neck squamous cell carcinoma; FFS, failure free survival; OS, overall survival; PFS, progression free survival; RT, radiotherapy.